PMID- 29803203
OWN - NLM
STAT- MEDLINE
DCOM- 20190225
LR  - 20221207
IS  - 2008-823X (Electronic)
IS  - 1028-852X (Print)
IS  - 1028-852X (Linking)
VI  - 23
IP  - 1
DP  - 2019 Jan
TI  - The Effects of Lactobacillus casei on Glycemic Response, Serum Sirtuin1 and 
      Fetuin-A Levels in Patients with Type 2 Diabetes Mellitus: A Randomized 
      Controlled Trial.
PG  - 68-77
AB  - BACKGROUND: Type 2 diabetes mellitus (T2DM) is related to the gut microbiota with 
      numerous molecular mechanisms. Modulating the gut microbiota by probiotics could 
      be effective in management of T2DM. The aim of the present trial was to evaluate 
      the effect of Lactobacillus casei on glycemic control and serum sirtuin1 (SIRT1) 
      and fetuin-A in patients with T2DM. METHODS: Forty patients with T2DM (n = 20 for 
      each group) were divided into intervention (probiotic) and placebo groups. The 
      intervention group received a daily capsule containing 108 cfu of L. casei for 
      eight weeks. The patients in placebo group took capsules containing maltodextrin 
      for the same time duration. Anthropometric measurements, dietary intake 
      questionnaires, and blood samples were collected, and the patients were assessed 
      by an endocrinologist at the beginning and at the end of the trial. RESULTS: 
      Fasting blood sugar, insulin concentration, and insulin resistance significantly 
      decreased in probiotic group compared with placebo group (-28.32 [-50.23 to 
      -6.41], 0.013; -3.12 [-5.90 to -0.35], 0.028; -32.31 [-55.09 to -9.54], 0.007, 
      respectively). Moreover, HbA1c reduced after intervention, but the reduction was 
      not significant (-0.45 [-0.96 to 0.05], 0.077). In comparison with placebo, the 
      L. casei supplementation significantly increased SIRT1 and decreased fetuin-A 
      levels at the end of the trial (0.52 [0.026 to 1.02], 0.040; -17.56 [-32.54 to 
      -2.58], 0.023, respectively). CONCLUSION: L. casei supplementation affected SIRT1 
      and fetuin-A levels in a way that improved glycemic response in subjects with 
      T2DM. Affecting the SIRT1 and fetuin-A levels introduces a new known mechanism of 
      probiotic action in diabetes management.
FAU - Khalili, Leila
AU  - Khalili L
AD  - Department of Nutrition, Faculty of Nutrition and Food Sciences, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
FAU - Alipour, Beitullah
AU  - Alipour B
AD  - Department of Community Nutrition, Faculty of nutrition and food sciences, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
FAU - Asghari Jafar-Abadi, Mohammad
AU  - Asghari Jafar-Abadi M
AD  - Department of statistics and Epidemiology, Faculty of Health, Tabriz University 
      of Medical Sciences, Tabriz, Iran.
FAU - Faraji, Ismail
AU  - Faraji I
AD  - Internist, fellow of Endocrinology, Tabriz University of Medical Sciences, 
      Tabriz, Iran.
FAU - Hassanalilou, Tohid
AU  - Hassanalilou T
AD  - Department of Nutrition, Faculty of Nutrition and Food Sciences, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
FAU - Mesgari Abbasi, Mehran
AU  - Mesgari Abbasi M
AD  - Drug Applied Research Center,Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Vaghef-Mehrabany, Elnaz
AU  - Vaghef-Mehrabany E
AD  - Department of Nutrition, Biochemistry and Diet Therapy, Faculty of nutrition and 
      food science, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Alizadeh Sani, Mahmood
AU  - Alizadeh Sani M
AD  - Department of Food Science and Technology, Faculty of nutrition and food 
      sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20180527
PL  - Iran
TA  - Iran Biomed J
JT  - Iranian biomedical journal
JID - 9814853
RN  - 0 (alpha-2-HS-Glycoprotein)
RN  - EC 3.5.1.- (Sirtuin 1)
SB  - IM
MH  - Adult
MH  - Diabetes Mellitus, Type 2/*blood/*microbiology
MH  - Female
MH  - Humans
MH  - Hyperglycemia/*blood/*microbiology
MH  - Lacticaseibacillus casei/*physiology
MH  - Male
MH  - Middle Aged
MH  - Sirtuin 1/*blood
MH  - alpha-2-HS-Glycoprotein/*metabolism
PMC - PMC6305821
OTO - NOTNLM
OT  - Lactobacillus casei
OT  - Probiotics
OT  - Type 2 diabetes mellitus
COIS- CONFLICT OF INTEREST. None declared.
EDAT- 2018/05/29 06:00
MHDA- 2019/02/26 06:00
PMCR- 2019/01/01
CRDT- 2018/05/28 06:00
PHST- 2018/05/28 06:00 [entrez]
PHST- 2018/05/29 06:00 [pubmed]
PHST- 2019/02/26 06:00 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - IBJ-23-68 [pii]
AID - 10.29252/.23.1.68 [doi]
PST - ppublish
SO  - Iran Biomed J. 2019 Jan;23(1):68-77. doi: 10.29252/.23.1.68. Epub 2018 May 27.